La Jolla, CA, United States of America

Edward A Lally

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 42(Granted Patents)


Location History:

  • San Diego, CA (US) (2008)
  • La Jolla, CA (US) (2010 - 2017)

Company Filing History:


Years Active: 2008-2017

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Edward A Lally: Innovator in Pharmaceutical Chemistry

Introduction

Edward A Lally is a prominent inventor based in La Jolla, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that modulate serotonin receptor activity. With a total of 6 patents to his name, Lally's work has the potential to impact various therapeutic areas.

Latest Patents

Lally's latest patents focus on processes for preparing phenyl-pyrazoles of Formula (I) and their salts, which are useful as modulators of 5-HT serotonin receptor activity. These inventions also encompass intermediates used in the preparation processes, as well as crystalline forms of the 5-HT serotonin receptor modulators and their compositions. This innovative work highlights the importance of his research in developing new pharmaceutical compositions.

Career Highlights

Edward A Lally is currently associated with Arena Pharmaceuticals, Inc., where he continues to advance his research in pharmaceutical innovations. His expertise in the field has led to the development of novel compounds that could enhance therapeutic options for patients.

Collaborations

Lally has collaborated with notable colleagues such as Tawfik Gharbaoui and Dipanjan Sengupta. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical sector.

Conclusion

Edward A Lally is a distinguished inventor whose work in pharmaceutical chemistry is paving the way for new treatments. His contributions, particularly in serotonin receptor modulation, are significant in the ongoing quest for effective therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…